Atractylenolide I ameliorated the growth and enzalutamide resistance of castration-resistant prostate cancer by targeting KIF15
These findings identified ATR-I as a promising therapeutic drug for overcoming enzalutamide resistance in CRPC patients and increased our understanding about its antitumor mechanisms.
Authors
- Yuxuan Deng (ORCID: https://orcid.org/0000-0002-8635-0233)
- Chenglin Han (ORCID: https://orcid.org/0000-0003-0757-8692)
- Bintao Hu
- Chengbao Li
- Bin Yang (ORCID: https://orcid.org/0000-0002-3944-8035)
- Xiaming Liu (ORCID: https://orcid.org/0000-0002-1194-8791)
- Jihong Liu (ORCID: https://orcid.org/0000-0003-3464-2901)
- Tao Wang (ORCID: https://orcid.org/0000-0003-2952-8397)
- Peng Hu (ORCID: https://orcid.org/0000-0002-5799-9703)
- Huixing Yuan (ORCID: https://orcid.org/0009-0004-4343-421X)
Institutions
- Shandong Provincial Hospital (CN)
- Tongji Hospital (CN)
- Shandong First Medical University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Chinese Medicine
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1186/s13020-025-01086-1
- Citations
- 4
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province